HK1025994A1 - A tumor necrosis factor related ligand - Google Patents
A tumor necrosis factor related ligandInfo
- Publication number
- HK1025994A1 HK1025994A1 HK00102948A HK00102948A HK1025994A1 HK 1025994 A1 HK1025994 A1 HK 1025994A1 HK 00102948 A HK00102948 A HK 00102948A HK 00102948 A HK00102948 A HK 00102948A HK 1025994 A1 HK1025994 A1 HK 1025994A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- necrosis factor
- tumor necrosis
- factor related
- related ligand
- trell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2354196P | 1996-08-07 | 1996-08-07 | |
US2851596P | 1996-10-18 | 1996-10-18 | |
US4082097P | 1997-03-18 | 1997-03-18 | |
PCT/US1997/013945 WO1998005783A1 (en) | 1996-08-07 | 1997-08-07 | A tumor necrosis factor related ligand |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1025994A1 true HK1025994A1 (en) | 2000-12-01 |
Family
ID=27362110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00102948A HK1025994A1 (en) | 1996-08-07 | 2000-05-17 | A tumor necrosis factor related ligand |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP0956351B1 (zh) |
JP (3) | JP4161084B2 (zh) |
KR (1) | KR100543730B1 (zh) |
CN (2) | CN101024831A (zh) |
AT (1) | ATE307204T1 (zh) |
AU (1) | AU736289B2 (zh) |
BG (1) | BG64779B1 (zh) |
BR (1) | BR9711046A (zh) |
CA (1) | CA2262756C (zh) |
CZ (1) | CZ297387B6 (zh) |
DE (1) | DE69734397T2 (zh) |
DK (1) | DK0956351T3 (zh) |
EA (1) | EA003187B1 (zh) |
EE (1) | EE05276B1 (zh) |
ES (1) | ES2251737T3 (zh) |
HK (1) | HK1025994A1 (zh) |
HU (1) | HU226787B1 (zh) |
IL (1) | IL128407A (zh) |
IS (1) | IS2606B (zh) |
NO (2) | NO326967B1 (zh) |
NZ (1) | NZ334107A (zh) |
PL (1) | PL188102B1 (zh) |
SI (1) | SI0956351T1 (zh) |
SK (1) | SK288012B6 (zh) |
TR (1) | TR199900903T2 (zh) |
WO (1) | WO1998005783A1 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011791A2 (en) * | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
DE69840631D1 (de) * | 1997-10-10 | 2009-04-16 | Genentech Inc | Apo-3 ligand |
DE19829550C1 (de) * | 1998-07-02 | 2000-01-27 | Bosch Gmbh Robert | Vorrichtung zum Verbinden von Bauteilen |
AU2507700A (en) | 1999-01-15 | 2000-08-01 | Biogen, Inc. | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
MXPA02005069A (es) * | 1999-11-19 | 2003-09-25 | Wegmann Keith W | Agentes de enlace especificos para t3 y metodos para su uso. |
US6994976B1 (en) | 1999-11-19 | 2006-02-07 | Tittle Thomas V | Tr3-specific binding agents and methods for their use |
ES2433011T3 (es) * | 1999-12-20 | 2013-12-05 | Immunex Corporation | Receptor TWEAK |
US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
CA2408228A1 (en) | 2000-05-08 | 2001-11-15 | Biogen, Inc. | Method for promoting neovascularization |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
KR101174214B1 (ko) | 2002-04-09 | 2012-08-14 | 바이오겐 아이덱 엠에이 인코포레이티드 | Tweak-관련 상태를 치료하는 방법 |
AU2003277828B2 (en) * | 2002-10-29 | 2009-06-04 | Anaphore, Inc. | Trimeric binding proteins for trimeric cytokines |
DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
ES2432564T3 (es) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Tratamiento y evaluación de trastornos inflamatorios |
CN103242447B (zh) | 2005-05-27 | 2016-04-27 | 比奥根Ma公司 | 结合tweak的抗体 |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
US8093006B2 (en) | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
CN103154029B (zh) | 2010-10-05 | 2015-11-25 | 弗·哈夫曼-拉罗切有限公司 | 抗人tweak的抗体及其用途 |
WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
US11028395B2 (en) * | 2016-10-24 | 2021-06-08 | Biois Co., Ltd. | TNF-alpha-binding aptamer, and therapeutic use for same |
JP7397446B2 (ja) * | 2018-04-20 | 2023-12-13 | 中央研究院 | Tnf関連炎症性疾患を治療または診断するtnf指向性アプタマーおよびその使用 |
JP2024516548A (ja) | 2021-04-08 | 2024-04-16 | ジョスリン ダイアビーティス センター インコーポレイテッド | 腎機能低下の診断及び予測の方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
IE902820A1 (en) | 1989-08-07 | 1991-02-27 | Merck & Co Inc | Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
CA2077322A1 (en) | 1991-09-04 | 1993-03-05 | Allen I. Oliff | Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins |
-
1997
- 1997-08-07 CA CA2262756A patent/CA2262756C/en not_active Expired - Lifetime
- 1997-08-07 AT AT97935334T patent/ATE307204T1/de active
- 1997-08-07 BR BR9711046-9A patent/BR9711046A/pt not_active Application Discontinuation
- 1997-08-07 ES ES97935334T patent/ES2251737T3/es not_active Expired - Lifetime
- 1997-08-07 EA EA199900187A patent/EA003187B1/ru not_active IP Right Cessation
- 1997-08-07 DK DK97935334T patent/DK0956351T3/da active
- 1997-08-07 PL PL97331583A patent/PL188102B1/pl unknown
- 1997-08-07 HU HU9903921A patent/HU226787B1/hu unknown
- 1997-08-07 SK SK157-99A patent/SK288012B6/sk not_active IP Right Cessation
- 1997-08-07 KR KR1019997001045A patent/KR100543730B1/ko not_active IP Right Cessation
- 1997-08-07 JP JP50823998A patent/JP4161084B2/ja not_active Expired - Lifetime
- 1997-08-07 AU AU38294/97A patent/AU736289B2/en not_active Ceased
- 1997-08-07 CN CNA2007100059560A patent/CN101024831A/zh active Pending
- 1997-08-07 CN CNB971984018A patent/CN1308451C/zh not_active Expired - Lifetime
- 1997-08-07 EP EP97935334A patent/EP0956351B1/en not_active Expired - Lifetime
- 1997-08-07 IL IL128407A patent/IL128407A/en not_active IP Right Cessation
- 1997-08-07 EP EP05011540.1A patent/EP1591530B8/en not_active Expired - Lifetime
- 1997-08-07 WO PCT/US1997/013945 patent/WO1998005783A1/en active IP Right Grant
- 1997-08-07 TR TR1999/00903T patent/TR199900903T2/xx unknown
- 1997-08-07 DE DE69734397T patent/DE69734397T2/de not_active Expired - Lifetime
- 1997-08-07 SI SI9730718T patent/SI0956351T1/sl unknown
- 1997-08-07 CZ CZ0040399A patent/CZ297387B6/cs not_active IP Right Cessation
- 1997-08-07 NZ NZ334107A patent/NZ334107A/en not_active IP Right Cessation
- 1997-08-07 EE EEP199900043A patent/EE05276B1/xx unknown
-
1999
- 1999-02-05 IS IS4967A patent/IS2606B/is unknown
- 1999-02-05 NO NO990550A patent/NO326967B1/no not_active IP Right Cessation
- 1999-02-11 BG BG103169A patent/BG64779B1/bg unknown
-
2000
- 2000-05-17 HK HK00102948A patent/HK1025994A1/xx not_active IP Right Cessation
-
2007
- 2007-02-07 JP JP2007028621A patent/JP4411330B2/ja not_active Expired - Lifetime
-
2008
- 2008-11-21 NO NO20084906A patent/NO20084906L/no not_active Application Discontinuation
-
2009
- 2009-03-27 JP JP2009080644A patent/JP2009183294A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1025994A1 (en) | A tumor necrosis factor related ligand | |
WO1999012965A3 (en) | April- a novel protein with growth effects | |
WO1999012964A3 (en) | Kay - a novel immune system protein | |
AU5901994A (en) | Tumor necrosis factor muteins | |
AU3447389A (en) | Tumor necrosis factor formulations | |
AU638982B2 (en) | Use of cytokines | |
ZA978805B (en) | Variable sector plate quad sector air preheater. | |
EP0596962A4 (en) | Therapeutic compositions and methods. | |
AU1467000A (en) | A novel tumor necrosis factor family member, drl, and related compositions and methods | |
AU7705098A (en) | Human tumor necrosis factor receptor-like protein 8 | |
AU4887290A (en) | Improved lamp system for operating theatres and the like | |
AU3039592A (en) | R.f. mixer | |
FR2701264B1 (fr) | Muteines de facteur de necrose tumorale. | |
AU7624598A (en) | 1,4-diazabicyclo (2.2.2) Oct-2-ylmethyl derivatives, their preparation and the rapeutic application | |
EP0961782A4 (en) | TR2 RECEPTOR OF TUMOR NECROSIS FACTOR IN MAN | |
AU3003095A (en) | Proteins associated with tumor necrosis factor receptor | |
AU1541699A (en) | Human tumor necrosis factor-r2-like proteins | |
AU4609693A (en) | An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it | |
EP1009431A4 (en) | ANTIBODIES AGAINST THE TYPE 2 (TR2) HUMAN TUMORNESCROSE FACTOR RECEPTOR | |
EP0663210A3 (en) | Inhibitor of tumor necrosis factor production. | |
ZA972708B (en) | Pharmaceutical compositions and methods for the manufacture thereof. | |
AU5434290A (en) | Therapeutic compounds, compositions and uses thereof | |
ZA949229B (en) | Tumor necrosis factor-gamma | |
GB2217325B (en) | Synthetic gene for tumour necrosis factor alpha. | |
IE891174L (en) | Tumor necrosis factor formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20170806 |